Literature DB >> 14557426

Are adult patients with Laron syndrome osteopenic? A comparison between dual-energy X-ray absorptiometry and volumetric bone densities.

Carlos A Benbassat1, Varda Eshed, Moshe Kamjin, Zvi Laron.   

Abstract

Severe short stature resulting from a deficiency in IGF-I is a prominent feature of Laron syndrome (LS). Although low bone mineral density (BMD) has been noted in LS patients examined by dual energy x-ray absorptiometry (DEXA), this technique does not take volume into account and may therefore underestimate the true bone density in patients with small bones. The aim of the present study was to evaluate the BMD yielded by DEXA in our LS patients using estimated volumetric values. Volumetric density was calculated with the following formulas: bone mineral apparent density (BMAD) = bone mineral content (BMC)/(area)(3/2) for the lumbar spine and BMAD = BMC/area(2) for the femoral neck. The study sample included 12 patients (mean age, 43.9 yr; mean height, 123.7 cm). Findings were compared with 10 osteopenic subjects without developmental abnormalities (mean age, 56 yr; mean height, 164.8 cm) and 10 healthy control subjects matched for sex and age to the LS patients (mean height, 165.5 cm). BMAD in the LS group was 0.201 +/- 0.02 g/cm(3) at the lumbar spine and 0.201 +/- 0.04 g/cm(3) at the femoral neck; corresponding values for the osteopenic group were 0.130 +/- 0.01 and 0.140 +/- 0.01 g/cm(3), and for the controls, 0.178 +/- 0.03 and 0.192 +/- 0.02 g/cm(3). Although areal BMD was significantly lower in the LS and osteopenic subjects compared with controls (P < 0.02) at both the lumbar spine and femoral neck, BMAD was low (P < 0.01) in the osteopenic group only. In conclusion, DEXA does not seem to be a reliable measure of osteoporosis in patients with LS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557426     DOI: 10.1210/jc.2003-030623

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  The insulin-like growth factor system in bone: basic and clinical implications.

Authors:  Masanobu Kawai; Clifford J Rosen
Journal:  Endocrinol Metab Clin North Am       Date:  2012-05-15       Impact factor: 4.741

Review 2.  Skeletal disorders associated with the growth hormone-insulin-like growth factor 1 axis.

Authors:  Gherardo Mazziotti; Andrea G Lania; Ernesto Canalis
Journal:  Nat Rev Endocrinol       Date:  2022-03-14       Impact factor: 43.330

3.  Abnormalities of the axial and proximal appendicular skeleton in adults with Laron syndrome (growth hormone insensitivity).

Authors:  L Kornreich; O Konen; M Schwarz; Y Siegel; G Horev; I Hershkovitz; Z Laron
Journal:  Skeletal Radiol       Date:  2007-11-09       Impact factor: 2.199

Review 4.  Insulin-like growth factor-I and bone: lessons from mice and men.

Authors:  Masanobu Kawai; Clifford J Rosen
Journal:  Pediatr Nephrol       Date:  2008-11-15       Impact factor: 3.714

5.  Lifetime, untreated isolated GH deficiency due to a GH-releasing hormone receptor mutation has beneficial consequences on bone status in older individuals, and does not influence their abdominal aorta calcification.

Authors:  Anita H O Souza; Maria I T Farias; Roberto Salvatori; Gabriella M F Silva; João A M Santana; Francisco A Pereira; Francisco J A de Paula; Eugenia H O Valença; Enaldo V Melo; Rita A A Barbosa; Rossana M C Pereira; Miburge B Gois-Junior; Manuel H Aguiar-Oliveira
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

6.  Genetic variations at the human growth hormone receptor (GHR) gene locus are associated with idiopathic short stature.

Authors:  Christel Dias; Mara Giordano; Rosalie Frechette; Simonetta Bellone; Constantin Polychronakos; Laurent Legault; Cheri L Deal; Cynthia Gates Goodyer
Journal:  J Cell Mol Med       Date:  2017-05-29       Impact factor: 5.310

7.  Dual-energy X-ray absorptiometry (DXA) to measure bone mineral density (BMD) for diagnosis of osteoporosis - experimental data from artificial vertebrae confirms significant dependence on bone size.

Authors:  Paul Henry Golding
Journal:  Bone Rep       Date:  2022-07-25

8.  Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.

Authors:  Danilo Fintini; Claudia Brufani; Marco Cappa
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

9.  Deficits in Bone Geometry in Growth Hormone-Deficient Prepubertal Boys Revealed by High-Resolution Peripheral Quantitative Computed Tomography.

Authors:  Tamar G Baer; Sanchita Agarwal; Shaoxuan Chen; Codruta Chiuzan; Aviva B Sopher; Rachel Tao; Abeer Hassoun; Elizabeth Shane; Ilene Fennoy; Sharon E Oberfield; Patricia M Vuguin
Journal:  Horm Res Paediatr       Date:  2020-03-30       Impact factor: 2.852

Review 10.  Laron syndrome - A historical perspective.

Authors:  Zvi Laron; Haim Werner
Journal:  Rev Endocr Metab Disord       Date:  2020-09-22       Impact factor: 6.514

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.